Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,979.20
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹134.35B
Enterprise Value₹140.07B
Total Cash (Recent Filing)₹3.81B
Total Debt (Recent Filing)₹16.07M
Price to Earnings (P/E)51.7
Beta1.13
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)30.92
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.23
Revenue Forecast (FY)₹13.05B
Bulls Say, Bears Say
Bulls Say
Specialized Fermentation API CapabilityConcord’s core emphasis on fermentation-derived, complex APIs creates high technical barriers to entry and sticky customer relationships. These capabilities support long-term pricing power, limited competition for niche molecules, and sustainable revenue opportunities as bioprocess demand grows.
Conservative Balance SheetAn exceptionally conservative capital structure with minimal leverage reduces financial risk, preserves strategic optionality for capex or acquisitions, and shields the company during industry cyclicality. This underpins durable resilience and ability to fund long-term process investments.
Solid Operating Cash GenerationConsistent positive operating cash flow—generally exceeding net income—and a 2026 FCF rebound indicate underlying earnings quality and internal funding capacity. Reliable cash generation supports reinvestment in fermentation scale-up and R&D without heavy external financing.
Bears Say
Recent Revenue DeclineA double-digit revenue decline in the most recent period signals a break in prior expansion and raises questions about demand sustainability or product mix. If persistent, this can constrain reinvestment, slow capacity utilization gains, and impair long-term growth trajectory.
Earnings WeaknessNearly 30% EPS contraction reflects margin pressure or one-off impacts reducing profitability. Sustained EPS weakness hampers retained-earnings accumulation, limits funding for R&D or capacity, and can signal operational challenges in converting specialized capabilities into consistent profit growth.
Free-cash-flow VolatilityVolatile free cash flow—including a negative year and intermittent declines—indicates swings in working capital or reinvestment timing. This unpredictability can complicate long-term planning for capex-heavy fermentation scale-ups and constrain steady capital returns or debt servicing plans.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1979.20 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹134.35B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on May 29, 2026. The company reported ₹8.5 earnings per share for the quarter, missing the consensus estimate of ₹8.9 by -₹0.4.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹7.542 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹8.5 in its last earnings report, missing expectations of ₹8.9. Following the earnings report the stock price went down -4.598%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―